Chronic Kidney Disease

Chronic kidney disease (CKD) is a health condition that involves reduced function of the kidneys. There are various causes of reduced kidney function and the severity of the condition can vary greatly.

Chronic Kidney Disease (CKD)

Chronic kidney disease is a health condition that involves the reduced function of the kidneys.

Living with Chronic Kidney Disease

Chronic Kidney Disease Symptoms

Chronic Kidney Disease Causes

Chronic Kidney Disease Diagnosis

Chronic Kidney Disease Treatment

Chronic Kidney Disease Prevention

Chronic Kidney Disease Patients and Exercise

Importance of Early Detection for Kidney Disease

Investigating the Epidemic for Chronic Kidney Disease

Risk Factors for Chronic Kidney Disease

Latest Chronic Kidney Disease News and Research

In settling fraud case, New York Medicare Advantage insurer, CEO will pay up to $100M

A western New York health insurance provider for seniors and the CEO of its medical analytics arm have agreed to pay a total of up to $100 million to settle Justice Department allegations of fraudulent billing for health conditions that were exaggerated or didn't exist.

20 Dec 2024

Breakthrough pig kidney transplant ends dialysis for Alabama woman

An Alabama woman is free from dialysis and in better health after surgeons at NYU Langone Health performed a gene-edited pig kidney transplant last month.

17 Dec 2024

A comprehensive review of atrial fibrillation

In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime.

17 Dec 2024

Repeated paracetamol use linked to health risks in older adults

New research, led by experts at the University of Nottingham, has found that repeated doses of paracetamol in people aged 65 and over, can lead to an increased risk of gastrointestinal, cardiovascular and renal complications.

12 Dec 2024

Disrupted sleep-wake rhythms linked to liver disease progression

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles. MASLD (formerly known as non-alcoholic fatty liver disease) is already the most common liver disorder: it affects 30% of adults and between 7% and 14% of children and adolescents, and this prevalence is predicted to rise to more than 55% of adults by 2040.

4 Dec 2024

Disrupted sleep patterns identified in patients with metabolic dysfunction-associated steatotic liver disease

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles.

2 Dec 2024

Low levels of arsenic exposure linked to increased kidney cancer risk

New research findings from the Texas A&M University School of Public Health indicate that exposure to even low levels of arsenic poses significant health risks, including an increased risk of kidney cancer.

2 Dec 2024

Study reveals pathways behind organ damage in severe COVID-19

New research published in the journal Proceedings of the National Academy of Sciences sheds light on the pathways that drive organ damage and death in severe COVID-19 and helps explain why survivors of the disease can experience long-term complications.

2 Dec 2024

Homebound seniors living alone often slip through health system’s cracks

Carolyn Dickens, 76, was sitting at her dining room table, struggling to catch her breath as her physician looked on with concern.

2 Dec 2024

Expert explores the expanding applications of GLP1 therapies

Researchers review recent advancements in glucagon-like peptide-1-based therapies.

28 Nov 2024

GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

27 Nov 2024

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.

25 Nov 2024

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering potential new treatments for asthma.

19 Nov 2024

BMI's influence on disease pathogenesis uncovered in new research

The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions like heart failure and osteoarthritis.

14 Nov 2024

$Gabapentinoids may increase hip fracture risk in older adults$

Gabapentinoids may increase hip fracture risk in older adults

The study, published today in JAMA Network Open, tracked patients hospitalized for hip fractures in Victoria, Australia from March 2013 through June 2018, who had used gabapentinoids before the injury.

13 Nov 2024

GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death in adults who had an initial stroke, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024.

11 Nov 2024

CKM syndrome leads to elevated cardiovascular disease risk earlier in life

People with chronic kidney disease, Type 2 diabetes or both were predicted to have elevated cardiovascular disease (CVD) risk 8 to 28 years sooner than someone without those conditions, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024.

11 Nov 2024